Recent Updates
Recently added Catalysts

PRV-101

Phase 1

Viral; Infection, Coxsackie(Virus) | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Jul 24, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment32
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04690426PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteersPHASE1 COMPLETED 32Dec 1, 2020Dec 1, 2021Jul 24, 2022 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
PRV-101BIOLOGICALCoxsackie Virus B vaccine
PlaceboOTHERPlacebo
Unlock Study Design Details